Fig. 4. Efficacy of C12G6 compared with and in combination with oseltamivir in mice. Efficacy of C12G6 compared with and in combination with oseltamivir.

Slides:

Advertisements

Similar presentations

Fig. 6. Transgenic expression of αLNNd and mag in dyW/dyW mice improves muscle function, increases body weight, and prolongs life span. Transgenic expression.

Advertisements

Fig. 7. Intrapatient variation in key contact signatures for PGDM1400 and PGT121. Intrapatient variation in key contact signatures for PGDM1400 and PGT121.

Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.

Fig. 5. Protective efficacy of the combination of PGT121 + PGDM1400 against a mixed SHIV challenge in rhesus monkeys. Protective efficacy of the combination.

Fig. 2 LYM attractor metagene.

Fig. 5. Correlation between CD34+CD45RA−CD90+ cell dose, engraftment success, and onset of neutrophil/platelet recovery in nonhuman primates. Correlation.

Fig. 3 Urinary LAM concentration predicted pulmonary TB and correlated to mycobacterial burden and weight loss. Urinary LAM concentration predicted pulmonary.

Fig. 5. Correlation of tail and long bone growth velocities with Cxm serum concentrations in mice. Correlation of tail and long bone growth velocities.

Fig. 2. VEGF-C/VEGFR-3 signaling increases responsiveness of melanoma to immunotherapy. VEGF-C/VEGFR-3 signaling increases responsiveness of melanoma to.

In vivo prophylactic and therapeutic efficacy of C12G6 in mice

Fig. 6. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex vivo. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex.

Fig. 5. Prophylactic treatment with GS-5734 reduces SARS-CoV disease.

Fig. 8. In vivo suppression of MM by CMLD

Fig. 2 Maraba treatment results in complete responses in the window of opportunity setting. Maraba treatment results in complete responses in the window.

MRSA virulence proteins cause LMC death and diminished CLV function

Fig. 6. Increased efficacy of immunotherapy in lymphangiogenic B16 melanomas depends on CCR7 signaling before therapy and local activation and expansion.

Fig. 4 Infection-induced CLV dysfunction is associated with decreased LMC coverage. Infection-induced CLV dysfunction is associated with decreased LMC.

Survival of mice after infection with M

Maraba treatment sensitizes 4T1 tumors to immune checkpoint blockade

(A) Weight loss curves following intranasal infection of different mouse groups with COBRA, seasonal, or pandemic influenza viruses. (A) Weight loss curves.

Fig. 5. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic mice. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic.

Fig. 7 Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors. Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors.

Fig. 1. Serum HBsAg, HBcrAg, and HBeAg reduction in human patients treated with a single dose of ARC-520. Serum HBsAg, HBcrAg, and HBeAg reduction in human.

Fig. 5 Combination intravenous reovirus and checkpoint inhibition in an orthotopic syngeneic brain tumor model. Combination intravenous reovirus and checkpoint.

Fig. 6. Epitope mapping of C12G6.

Protection from influenza virus challenge.

Fig. 4. MATE1 transcription in RCC.

Fig. 7 pDCs are critical for the maintenance of skin fibrosis and for the presence of CXCL4 in the skin. pDCs are critical for the maintenance of skin.

Fig. 6 ROC curves of mCCNA1 and mVIM assayed on esophageal balloon samplings of the distal esophagus. ROC curves of mCCNA1 and mVIM assayed on esophageal.

Fig. 2. Best model fits. Best model fits. Illustration of the best model fits for the (A) basic, (B) continuous, and (C) cluster models. See Table 1 and.

Fig. 4. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in vivo. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in.

Antitumor effect of local cancer immunotherapy treatment toward distant B16F10 tumors. Antitumor effect of local cancer immunotherapy treatment toward.

Survival of BALB/c mice after HK/Syd challenge.

Fig. 7 BRD0705 impairs colony formation in AML cell lines and patient cells and shows in vivo efficacy in multiple AML mouse models. BRD0705 impairs colony.

Fig. 4 DMF enhances VSVΔ51 therapeutic efficacy in syngeneic and xenograft tumor models. DMF enhances VSVΔ51 therapeutic efficacy in syngeneic and xenograft.

Fig. 7. KIF11 informs patient prognosis, and targeting improves survival in a preclinical model. KIF11 informs patient prognosis, and targeting improves.

Fig. 7. ApoMSCs exert immunosuppressive activity in GvHD and elicit IDO in engulfing recipient phagocytes. ApoMSCs exert immunosuppressive activity in.

Indomethacin worsens the effects of C. difficile infection in mice.

Fig. 8 Combining M7824 with radiation or chemotherapy enhances antitumor efficacy. Combining M7824 with radiation or chemotherapy enhances antitumor efficacy.

Fig. 7. Inhibitory mechanisms of C12G6.

Fig. 5 Local gel scaffold for T cell memory response.

Fig. 3 M7824 inhibits tumor growth and metastasis and provides long-term antitumor immunity. M7824 inhibits tumor growth and metastasis and provides long-term.

Fig. 4. Improved tumor response to docetaxel in TNBC and trastuzumab in HER2-amplified PDX models with the addition of S Improved tumor response.

Fig. 4. Loss of DLK expression is neuroprotective in the SOD1G93A mouse model of ALS. Loss of DLK expression is neuroprotective in the SOD1G93A mouse model.

Fig. 8 SQLE inhibitor terbinafine suppresses NAFLD-HCC growth in vitro and in vivo. SQLE inhibitor terbinafine suppresses NAFLD-HCC growth in vitro and.

Fig. 1. In vitro binding and neutralization activities of C12G6.

Comparison of therapeutic efficacies of C12G6 and other bnAbs in mice

HECTD2 knockdown ameliorates Pseudomonas-induced lung injury in vivo

Fig. 6 Anticancer effects in PyMT-MMTV syngeneic and MDA-MB-231 xenograft-bearing mice. Anticancer effects in PyMT-MMTV syngeneic and MDA-MB-231 xenograft-bearing.

Fig. 3 Agonists of innate immunity are effective only when released locally from the hydrogel. Agonists of innate immunity are effective only when released.

Fig. 5. Prophylactic and therapeutic efficacy of C12G6 in ferrets.

IIV induces CD21hiCD27+ and CD21loCD27+ influenza-specific B cells

Fig. 5 Early and modest immune response at day 3 after exposure in Delayed animals. Early and modest immune response at day 3 after exposure in Delayed.

Fig. 4 cTFH1 cells correlate with a boosting of influenza-specific memory B cells. cTFH1 cells correlate with a boosting of influenza-specific memory B.

AN12855 is efficacious in acute and chronic murine models of TB infection. AN12855 is efficacious in acute and chronic murine models of TB infection. (A,

Effects of tumour size on response to treatment in the KPC model.

Antitumor effect of local cancer immunotherapy treatment in various tumor models. Antitumor effect of local cancer immunotherapy treatment in various tumor.

Protective effects of cysteine protease inhibitor Z-FA-FMK and E64d in SMNΔ7 mice. Protective effects of cysteine protease inhibitor Z-FA-FMK and E64d.

Genetic EGFR ablation in K-RAS–mutated lung AC reduces tumor growth

OVA-specific and InvaplexNAT-specific serum IgG endpoint titers in mice after intranasal immunization with OVA alone or OVA combined with InvaplexAR, InvaplexNAT,

Kaplan-Meier survival analysis for all-cause and CVD mortality in 2,823 type 2 diabetic patients stratified by CKD according to each creatinine-based equation.

A multimechanistic antibody targeting the receptor binding site potently cross-protects against influenza B viruses by Chenguang Shen, Junyu Chen, Rui.

In vivo assessment of synergistic activity of MV-CEA and RT in a U87 s

Functional characterization of multidonor class antibodies.

A, one-step viral growth curves: RT treatment increased the virus yield in MV-CEA–treated U87 cells by up to 2 log as compared with MV-CEA infection only.

Fig. 6 Multivalent DNA vaccine and protein antigen delivery by T4-AAV nanoparticles. Multivalent DNA vaccine and protein antigen delivery by T4-AAV nanoparticles.

Fig. 2 NDR2-deficient mice are more vulnerable to RNA viral infection.

In vivo prophylactic and therapeutic efficacy of C12G6 in mice

Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors. Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors.

Fig. 6. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex vivo. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex.

Presentation transcript:

Fig. 4. Efficacy of C12G6 compared with and in combination with oseltamivir in mice. Efficacy of C12G6 compared with and in combination with oseltamivir in mice. (A and B) Kaplan-Meier survival curves of mice that received C12G6 (10 mg/kg) (open symbols), oseltamivir (25 mg/kg) (closed symbols), or C5G6 (25 mg/kg) (no symbols) at the indicated day after intranasal infection with 25 MLD50 of MA-B/Florida/4/2006 (A) or MA-B/Brisbane/60/2008 (B). The control IgG is C5G6. dpi, days postinfection. (C to H) Survival curves (C and D), body weight change (E and F), and lung viral titers (G and H) of BALB/c mice (n = 5 per group) that received a single treatment of C12G6 or a control IgG (C5G6) intravenously at 2 mg/kg, oseltamivir orally at 25 mg/kg twice a day for 4 days, or a combined treatment of C12G6 and oseltamivir, starting from 2 days after intranasal infection with 25 MLD50 of MA-B/Florida/4/2006 or B/Brisbane/60/2008. The virus titers in lungs were determined on days 4 and 6 after infection. The black bars indicate mean values. The body weight curves represent mean ± 95% confidence interval of the mean. Statistically significant difference of the survival outcome was estimated with the log-rank test. The AUC analysis was used to determine the significance of body weight loss, and the t test was used to assess the significance of lung viral titers. *P < 0.05, **P < 0.01, and ***P < 0.001, compared to the control IgG–treated group. Chenguang Shen et al., Sci Transl Med 2017;9:eaam5752 Published by AAAS